XML 66 R41.htm IDEA: XBRL DOCUMENT
v3.25.3

Net Loss Per Share (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Schedule of Earnings Per Share, Basic and Diluted | The following table presents the computation of basic and diluted net loss per share for the years ended September 30, 2025, 2024 and 2023.
|  | Year Ended September 30,
|  | 2025 |  | 2024 |  | 2023
|  | (in thousands, except per share amounts)
Numerator: |  |  |  |  |  |
Net loss attributable to Arrowhead Pharmaceuticals, Inc. |  | $ | (1,631) |  |  | $ | (599,493) |  |  | $ | (205,275) |
Denominator: |  |  |  |  |  |
Weighted-average basic shares outstanding (1) |  | 133,758 |  |  | 119,784 |  |  | 106,750 |
Effect of dilutive securities |  | — |  |  | — |  |  | — |
Weighted-average diluted shares outstanding (1) |  | 133,758 |  |  | 119,784 |  |  | 106,750 |
Basic net loss per share |  | $ | (0.01) |  |  | $ | (5.00) |  |  | $ | (1.92) |
Diluted net loss per share |  | $ | (0.01) |  |  | $ | (5.00) |  |  | $ | (1.92) |
(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6.
Schedule of Antidilutive Securities Excluded from Computation of Income (Loss) Per Share | The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.
|  | Year Ended September 30,
|  | 2025 |  | 2024 |  | 2023
|  | (in thousands)
Options |  | 744 |  |  | 707 |  |  | 633 |
Restricted stock units |  | 4,276 |  |  | 4,030 |  |  | 3,420 |
Total |  | 5,020 |  |  | 4,737 |  |  | 4,053 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration